Amgen’s Kyprolis beats rival Velcade in comparative study

March 2, 2015 8:09 AM

15 0

On Sunday, Biotech giant Amgen released a statement saying that its cancer drug Kyprolis has been found to be more efficient in treating relapsed multiple myeloma than its major rival, and more established drug, Velcade in a new clinical research. Multiple myeloma is a cancer of the plasma cells in bone marrow.

Amgen said that the study has found that its cancer medication Kyprolis is twice as effective as Takeda Pharmaceutical Co. and Johnson & Johnson’s drug Velcade. The news release stated that cancer patients treated with Kyprolis following the onset of multiple myeloma second time were found living tw...

Read more

To category page